Page 1197 - Basic _ Clinical Pharmacology ( PDFDrive )

Index

Note: In this index, the letters “b,” “f ,” and “t ” denote text box, figures, and tables, respectively.

A Acetohexamide, 758, 768t. See also azelaic acid, 1078
Abacavir Sulfonylureas benzoyl peroxide, 1078
description of, 870, 871t Acetylator, slow, 68 brimonidine, 1078
HLA polymorphisms in hypersensitivity Acetylcholine (ACh), 35, 372. isotretinoin, 1077–1078
reactions to, 80t, 83t, 83–84, 84f See also Neuromuscular retinoic acid derivatives, 1077
Abaloparatide, 775, 790t blocking drugs Aconite, 1133t
Abarelix, 678–679 in CNS, 374f, 376t, 378 Acquired immunodeficiency syndrome
Abatacept, 649–650, 994 functions of, 92t (AIDS), 984–985. See also
Abbreviations, prescriptions, and chart structure of, 109, 109f, 476f Human immunodeficiency
order, 1149t Acetylcholine-blocking drugs, 124, virus (HIV)
ABC (ATP-binding cassette) family, 8 for parkinsonism, 501t, Acromegaly
ABCG2, 83 501–502, 508t description of, 672
ABCG5 mutation, 631 Acetylcholinesterase (AChE) dopamine agonists for, 679–680
ABCG8 mutation, 631 cholinomimetics on, 108f, 109 Action potential-prolonging drugs
Abciximab, 621, 995 description of, 95, 372 (class 3), arrhythmia treated
Abiraterone Acetylcholinesterase inhibitors, 5, 120 with, 243–245, 251t
adrenocortical antagonist actions of, Acid, weak amiodarone, 239t, 240t, 243–244,
704f, 716–717 examples of, 10t 251t
antiandrogen actions of, 743, 745t ionization of, 9–10 dofetilide, 239t, 240t, 245, 251t
prostate cancer treated with, 972 Acidosis, metabolic dronedarone, 239t, 240t, 244, 251t
Abortion, eicosanoids for, 334 hyperchloremic ibutilide, 239t, 240t, 245, 251t
Abraxane, 963 from carbonic anhydrase inhibitors, preparations available, 252t
Absence seizures, 410 261 sotalol, 239t, 240t, 244–245, 251t
Absorption, 7 from potassium-sparing diuretics, Action potentials
extent of, 47, 47f, 47t 267 cardiac, sodium channels in, 231f,
percutaneous, 1069f Acid-peptic disease, 1087 231–232
rate of, 47f, 48 Acid-peptic disease drugs, 1087–1095, resting potentials on, 232–233,
on target concentration, 52 1115t 233f
Abstinence syndrome, 559 intragastric acidity-reducing agents, Activated charcoal, 1040
Abuse, drug, 575. See Drugs of abuse 1087–1095, 1115t Activated partial thromboplastin time
Acamprosate, 404, 406t, 407t acid secretion, 1087–1088, 1088f (aPTT, PTT), 612, 613
Acarbose, 761, 768t antacids, 1088–1089 Activated protein C, 624
Acceptable daily intake (ADI), 1004 H 2 -receptor antagonists, 1089–1091 Activator. See also Agonist; specific
Accumulation, drug, 46f, 46–47 proton-pump inhibitors, activators
Accumulation factor, 47 1091–1095 allosteric, 5, 6f
Acebutolol, 164t. See also b-receptor mucosal protective agents chloride channel, 1099, 1103
antagonist drugs bismuth compounds, 1096 tissue plasminogen, 611, 611f, 619
description of, 164t, 166, 170t mechanisms of, 1095 Active immunization
hypertension treated with, 183 prostaglandin analogs, 1096 childhood, recommended schedule for,
Acetaldehyde, 397f, 398 sucralfate, 1095 1175, 1179t
Acetaminophen, 659, 664t Acid reducers, OTC definition of, 1175
case study regarding, 56, 73 H 2 -antagonists, 1122t Activin
metabolism of, 64, 65f proton-pump inhibitors, 1122t in ovary, 732
in neonates, 1053t Acid-reducing agents, 1157t in testis, 740
poisoning management for, 65f, 1040, Acid secretion, gastrointestinal, Acute angle-closure glaucoma, 118
1041t 1087–1088, 1088f Acute colonic pseudo-obstruction, 1097
preparations available, 664t Acitretin, 1078 Acute coronary syndrome
Acetazolamide Aclidinium, 130, 354, 359 description of, 195
description of, 260–261, 270, 272t Acne preparations vasodilators for, 207–208
epilepsy treated with, 432 antibacterial, 1071–1072 Acute dystonic reactions, 522

1183